Insight Molecular Diagnostics Inc. (IMDX)

Market Cap	196.63M +142.2%
Revenue (ttm)	1.95M -49.3%
Net Income	-47.84M
EPS	-1.46
Shares Out	32.29M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	371,152
Open	5.70
Previous Close	5.88
Day's Range	5.43 - 6.15
52-Week Range	2.33 - 8.51
Beta	1.63
Analysts	Buy
Price Target	8.33 (+36.78%)
Earnings Date	May 13, 2026

About IMDX

Insight Molecular Diagnostics Inc. operates as a precision diagnostics company in the United States and internationally. The company develops and commercializes laboratory developed tests, kitted research use only tests, and kitted clinical tests. It is developing DetermaCNI, a blood-based monitoring tool that detects progression early after one cycle cancer treatment; and DetermaIO, a gene expression test that assesses the tumor microenvironment to predict response to immunotherapies. The company also offers GraftAssureCore test, a blood test ...

• Industry: Diagnostics & Research
• Sector: Healthcare
• Founded: 2009
• Employees: 58
• Stock Exchange: NASDAQ
• Ticker Symbol: IMDX
• Website: https://www.imdxinc.com

Financial Performance

In 2025, IMDX's revenue was $4.06 million, an increase of 115.58% compared to the previous year's $1.88 million. Losses were -$50.22 million, -17.57% less than in 2024.

Analyst Summary

According to 4 analysts, the average rating for IMDX stock is "Buy." The 12-month stock price target is $8.33, which is an increase of 36.78% from the latest price.

Price Target

$8.33

(36.78% upside)

Analyst Consensus: Buy